Halozyme Therapeutics (HALO, Financial) experienced a significant stock price drop of 5.77%. The stock is now trading at $55.23 per share with a trading volume of 678,007 shares, reflecting a turnover rate of 0.53% and a price fluctuation of 5.61%.
According to recent financial reports, Halozyme reported revenue of $290 million, a net profit of $137 million, and earnings per share of $1.08. The company's gross profit stands at $223 million, with a price-to-earnings ratio of 18.82. In terms of analyst recommendations, 58% of the 12 institutions giving ratings suggest a buy, while 42% recommend holding the stock, and none suggest selling.
Within the biotechnology industry, where Halozyme operates, the sector as a whole saw a decline of 0.98%. Notable performers include companies like 60 Degrees Pharmaceuticals Inc, Psyence Biomedical Ltd, and Neurosense Therapeutics Ltd, which demonstrated significant gains. Particularly active stocks with high turnover rates were Molecular Templates, Inc. (4436.19%), Elevai Labs, Inc. (3353.48%), and Pulmatrix, Inc. (385.85%). Stocks with the highest volatility included Molecular Templates, Inc., Psyence Biomedical Ltd, and 60 Degrees Pharmaceuticals Inc, with fluctuations of 249.67%, 211.36%, and 188.46%, respectively.
Halozyme Therapeutics is a biotechnology company specializing in developing and commercializing novel cancer therapies. The company focuses on creating enzyme-based treatments targeting tumor transformations and licenses its technologies to pharmaceutical collaborators to advance product development, with its headquarters based in the United States.
